Related Experiment Video
Updated: Jun 16, 2025

Measurements of Physiological Stress Responses in C. Elegans
Published on: May 21, 2020
The deubiquitinating enzyme USP35 regulates the stability of NRF2 protein
Dian Zhang1, Jiawen Li1, Chao Zhang1
1Department of Thoracic Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Xigong District, Luoyang, China.
Abstract:
Many cancers exhibit resistance to chemotherapy, resulting in a poor prognosis. The transcription factor NRF2, activated in response to cellular antioxidants, plays a crucial role in cell survival, proliferation, and resistance to chemotherapy. This factor may serve as a promising target for therapeutic interventions in esophageal carcinoma. Recent research suggests that NRF2 activity is modulated by ubiquitination mediated by the KEAP1-CUL3 E3 ligase complex, highlighting the importance of deubiquitination. However, the specific deubiquitinase responsible for regulating NRF2 in esophageal cancer remains unknown. In this study, a novel regulator of the NRF2 protein, Ubiquitin-Specific Protease 35 (USP35), has been identified. Mechanistically, USP35 modulates NRF2 stability through enzymatic deubiquitination. USP35 interacts with NRF2 and facilitates its deubiquitination. Knockdown of USP35 leads to a notable increase in NRF2 levels and enhances the sensitivity of cells to chemotherapy. These findings suggest that the USP35-NRF2 axis is a key player in the regulation of therapeutic strategies for esophageal cancer.
Insights
Researchers identified Ubiquitin-Specific Protease 35 (USP35) as a key regulator of NRF2 in esophageal cancer. USP35 deubiquitinates NRF2, impacting chemotherapy resistance and offering a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cancer chemotherapy resistance leads to poor patient outcomes.
- The transcription factor NRF2 promotes cell survival and chemotherapy resistance.
- NRF2 activity is regulated by ubiquitination, but the specific deubiquitinase in esophageal cancer is unknown.
Purpose of the Study:
- To identify novel regulators of NRF2 in esophageal carcinoma.
- To elucidate the mechanism by which NRF2 stability is controlled.
- To explore the therapeutic potential of targeting the NRF2 pathway.
Main Methods:
- Investigated the role of Ubiquitin-Specific Protease 35 (USP35) in NRF2 regulation.
- Utilized biochemical assays to demonstrate USP35-mediated deubiquitination of NRF2.
- Performed USP35 knockdown experiments in esophageal cancer cells.
Main Results:
- Identified USP35 as a novel regulator of NRF2 stability.
- USP35 directly interacts with NRF2 and removes ubiquitin chains.
- Knockdown of USP35 increases NRF2 levels and enhances chemotherapy sensitivity.
Conclusions:
- The USP35-NRF2 axis is a critical regulator in esophageal cancer.
- USP35 deubiquitinase activity influences NRF2 stability and chemotherapy response.
- Targeting USP35 may represent a novel therapeutic strategy for esophageal carcinoma.
Related Concept Videos
Regulation of Nuclear Protein Sorting
Regulation of the Unfolded Protein Response
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
The Unfolded Protein Response
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

